Table 4.
Rank probability of the efficacy of biologic agents based on the number of patients who achieved a complete remission (A) response and the safety based on the number of SAE (B)
| Treatment | SUCRA |
|---|---|
| A. Efficacy | |
| IL-2 | 0.929 |
| Obinutuzumab | 0.754 |
| Rituximab | 0.612 |
| Belimumab | 0.581 |
| Anifrolumab | 0.505 |
| Abatacept | 0.280 |
| Ocrelizumab | 0.230 |
| Control | 0.110 |
| B. Safety | |
| IL-2 | 0.931 |
| Rituximab | 0.657 |
| Belimumab | 0.587 |
| Obinutuzumab | 0.529 |
| Control | 0.361 |
| Anifrolumab | 0.335 |
| Abatacept | 0.319 |
| Ocrelizumab | 0.282 |
SUCRA, surface under the cumulative ranking curve.